NUCB2/Nesfatin-1 Drives Breast Cancer Metastasis through the Up-Regulation of Cholesterol Synthesis via the mTORC1 Pathway

ELISA was employed to measure the concentration of Nesfatin-1 in the serum of breast cancer patients and the control group. Database analysis suggested that nucleobindin-2 (NUCB2)/Nesfatin-1 might be acetylated in breast cancer, which was confirmed by treating the breast cancer cells with acetyltransferase inhibitors.